Saturday 17 October 2026
Export ADIL’s income statement to Excel — free account
Adial Pharmaceuticals, Inc.
ADIL Healthcare Biotechnology
In the quarter to June 2026, EPS fell 150.0% and free cash flow fell 263.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.49
0.35
+11.15%
Follow ADIL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
4.34 | 4.42 | 3.18 | 5.63 |
Net Debt/EBITDA |
2.61 | 3.12 | 2.29 | 0.55 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.02 | 0.66 | 0.80 | 0.12 | |
Capex/Depreciation |
0.00 | 750.00 | 0.00 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(2.07) | (1.76) | (1.18) | (1.38) | |
Cash per Share |
5.19 | 8.80 | 3.35 | 6.21 | |
Shareholders Equity per Share |
5.08 | 7.89 | 2.71 | (8.30) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.08 | 7.89 | 2.71 | (8.30) | |
Free Cash Flow |
(1.83) | (1.17) | (1.61) | (6.36) | |
Working Capital |
3.86 | 4.78 | 3.29 | 23.72 | |
Capital Expenditures |
— | 0.15 | — | — | |
Net Current Asset Value |
3.86 | 4.78 | 3.29 | (38.62) | |
| Other line items | |||||
Quick Ratio |
3.99 | 4.21 | 3.04 | 5.61 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.07) | (1.98) | (1.18) | (1.38) | |
Capex per Share |
0.00 | 0.22 | 0.00 | 0.00 | |
Average Payables |
0.44 | 0.45 | 0.55 | 1.65 | |
Average Assets |
6.19 | 5.86 | 4.34 | 17.95 | |
Average Common Equity |
5.19 | 4.67 | 2.92 | (16.39) | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates